Ascendis Pharma A/S (ASND)
227.97
-1.26
(-0.55%)
USD |
NASDAQ |
Oct 12, 11:16
Ascendis Pharma Free Cash Flow (Quarterly) : 323.81M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 323.81M |
| March 31, 2026 | -18.06M |
| December 31, 2025 | 81.56M |
| September 30, 2025 | 1.519M |
| June 30, 2025 | -14.45M |
| March 31, 2025 | -15.80M |
| December 31, 2024 | -86.49M |
| September 30, 2024 | -61.91M |
| June 30, 2024 | -66.05M |
| March 31, 2024 | -110.47M |
| December 31, 2023 | -39.59M |
| September 30, 2023 | -138.07M |
| June 30, 2023 | -167.97M |
| March 31, 2023 | -158.93M |
| December 31, 2022 | -143.89M |
| September 30, 2022 | -100.54M |
| June 30, 2022 | -136.77M |
| March 31, 2022 | -151.01M |
| December 31, 2021 | -147.17M |
| September 30, 2021 | -128.87M |
| June 30, 2021 | -143.03M |
| March 31, 2021 | -103.80M |
| December 31, 2020 | -112.42M |
| September 30, 2020 | -73.63M |
| June 30, 2020 | -67.73M |
| Date | Value |
|---|---|
| March 31, 2020 | -80.34M |
| December 31, 2019 | -55.66M |
| September 30, 2019 | -68.50M |
| June 30, 2019 | -6.322M |
| March 31, 2019 | -72.22M |
| December 31, 2018 | -42.60M |
| September 30, 2018 | -55.71M |
| June 30, 2018 | -24.00M |
| March 31, 2018 | -45.28M |
| December 31, 2017 | -29.68M |
| September 30, 2017 | -29.87M |
| June 30, 2017 | -25.88M |
| March 31, 2017 | -22.95M |
| December 31, 2016 | -18.79M |
| September 30, 2016 | -17.46M |
| June 30, 2016 | -14.95M |
| March 31, 2016 | -16.55M |
| December 31, 2015 | -11.57M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -9.871M |
| September 30, 2014 | -4.579M |
| June 30, 2014 | -6.859M |
| March 31, 2014 | -3.639M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 133.86M |
| Novo Nordisk A/S | 6.362B |
| Evaxion AS | -- |
| Genmab A/S | 48.05M |
| Zealand Pharma A/S | 61.68M |